ALLO
Q3 2026 EPS Estimate
$-0.17
Aug 12, 2026 · Reports after close
Revenue Estimate
$2,500
FY2030E EPS$0.91

Analyst Sentiment

Wall St. Consensus
Buy
30 analysts·High coverage
65
Score
19 Buy (63%)10 Hold (33%)1 Sell (4%)
Rating Breakdown
Strong Buy
00%
Buy
1963%
Hold
1033%
Sell
13%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$3.85
+83.3%
Consensus
$6.42
+206.0%
Bull
$9.00
+328.6%
12-Month Target Range30 analysts
$3.85$6.42$9.00
Current $2.10Consensus
Current Price
$2.10
Upside to Consensus
$4.32

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+193663.33%
EPS
FY2028
Rev+618.88%
EPS
FY2029
Rev+317.36%
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029EFY2030E
Revenue Avg$6,000$12M$84M$349M$665M
Low$6,000$12M$84M$349M$665M
High$6,000$12M$84M$349M$665M
EBITDA Avg$-3,600$-7M$-50M$-209M$-399M
Low$-3,600$-7M$-50M$-209M$-399M
High$-3,600$-7M$-50M$-209M$-399M
EBIT Avg$-3,600$-7M$-50M$-209M$-399M
Low$-3,600$-7M$-50M$-209M$-399M
High$-3,600$-7M$-50M$-209M$-399M
Net Income Avg$-168M$-152M$-169M$-13M$200M
Low$-192M$-204M$-240M$-13M$200M
High$-136M$-100M$-64M$-13M$200M
EPS Avg$-0.72$-0.76$-0.71$-0.06$0.91
Low$-0.87$-0.93$-1.09$-0.06$0.91
High$-0.61$-0.45$-0.29$-0.06$0.91
Analysts (Rev / EPS)6 / 75 / 67 / 93 / 35 / 3
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027
Revenue Avg$2,500$2,500$5,000$6,667$6,667$6,667
Low$2,500$2,500$5,000$6,667$6,667$6,667
High$2,500$2,500$5,000$6,667$6,667$6,667
EBITDA Avg$-1,500$-1,500$-3,000$-4,000$-4,000$-4,000
Low$-1,500$-1,500$-3,000$-4,000$-4,000$-4,000
High$-1,500$-1,500$-3,000$-4,000$-4,000$-4,000
EBIT Avg$-1,500$-1,500$-3,000$-4,000$-4,000$-4,000
Low$-1,500$-1,500$-3,000$-4,000$-4,000$-4,000
High$-1,500$-1,500$-3,000$-4,000$-4,000$-4,000
Net Income Avg$-42M$-45M$-45M$-47M$-47M$-55M
Low$-52M$-45M$-45M$-47M$-47M$-55M
High$-35M$-45M$-45M$-47M$-47M$-55M
EPS Avg$-0.18$-0.19$-0.19$-0.20$-0.20$-0.23
Low$-0.22$-0.19$-0.19$-0.20$-0.20$-0.23
High$-0.14$-0.19$-0.19$-0.20$-0.20$-0.23
Analysts (Rev / EPS)9 / 57 / 18 / 14 / 34 / 38 / 1

Earnings Surprises

Recent Analyst Actions

Apr 14, 2026Bernstein
Allogene Therapeutics price target raised to $3.85 from $1.60 at Bernstein
Target:$3.85
+25.8%from $3.06
Apr 14, 2026Robert W. Baird
Allogene Therapeutics price target raised to $9 from $7 at Baird
Target:$9.00
+194.1%from $3.06
May 16, 2024H.C. Wainwright
Allogene (ALLO) PT Lowered to $9 at H.C. Wainwright
Target:$9.00
+202.0%from $2.98
May 14, 2024B.Riley Financial
Allogene (ALLO) PT Lowered to $7 at B.Riley
Target:$7.00
+141.4%from $2.90
Jun 13, 2022Robert W. Baird
Allogene Therapeutics (ALLO) Stock Price: $11 Target From Baird
Target:$11.00
+12.9%from $9.74
Jan 3, 2022Guggenheim
Allogene Therapeutics price target lowered to $35 from $40 at Guggenheim
Target:$35.00
+128.9%from $15.29
Dec 3, 2021Canaccord Genuity
Allogene Therapeutics clinical hold could be lifted shortly, says Canaccord
Target:$55.00
+212.1%from $17.62
Oct 8, 2021Roth Capital
Allogene Therapeutics price target lowered to $35 from $60 at Roth Capital
Target:$35.00
+166.6%from $13.13
Oct 8, 2021Bank of America Securities
Allogene (ALLO) PT Lowered to $32 at BofA Securities
Target:$32.00
+143.7%from $13.13
Oct 8, 2021Oppenheimer
Allogene Therapeutics price target lowered to $40 from $44 at Oppenheimer
Target:$40.00
+204.6%from $13.13
Oct 8, 2021Jefferies
Allogene (ALLO) PT Lowered to $30 at Jefferies
Target:$30.00
+128.5%from $13.13
Sep 23, 2021Raymond James
Allogene Therapeutics upgraded to Outperform from Market Perform at Raymond James
Target:$36.00
+30.2%from $27.64
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.